Formosa Pharmaceuticals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Erick Co

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Erick Co

1.8yrs

테뉴어

Dr. Erick Co, Ph D., serves as Director of New Drug Development at ScinoPharm Taiwan, Ltd. Dr. Co serves as the Chief Executive Officer of Formosa Pharmaceuticals, Inc. and has been its President since 202...

리더십 팀

이름	위치	테뉴어	보상	소유권
Erick Co	President & CEO	1.8yrs	데이터 없음	데이터 없음
Nai Hsien Tsao	Director of Finance & CFO	less than a year	데이터 없음	데이터 없음
Helen Liu	Manager of Legal & Corporate Communications	less than a year	데이터 없음	데이터 없음
Ching Cheng Wei	Chief Business & Strategy Officer	less than a year	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

경험이 풍부한 관리: 6838 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

Formosa Pharmaceuticals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Formosa Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: NT$0.37 loss per share (vs NT$1.07 loss in 3Q 2023)

Formosa Pharmaceuticals, Inc. Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain After Cataract Surgery

New major risk - Share price stability

Formosa Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 11, 2024

New minor risk - Shareholder dilution

New minor risk - Share price stability

Eyenovia, Inc. Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S

Second quarter 2024 earnings released: NT$0.72 loss per share (vs NT$0.57 loss in 2Q 2023)

Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

Full year 2023 earnings released: NT$2.59 loss per share (vs NT$3.82 loss in FY 2022)

Formosa Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Third quarter 2023 earnings released: NT$1.08 loss per share (vs NT$0.89 loss in 3Q 2022)

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

Full year 2022 earnings released: NT$3.82 loss per share (vs NT$4.33 loss in FY 2021)

Less than half of directors are independent

Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

Less than half of directors are independent

CEO

테뉴어

리더십 팀

평균 재임 기간